[1]王晓伟,高学军,张波,等.血浆差异表达miRNA预测脑膜瘤术后复发[J].中国临床神经外科杂志,2024,29(07):405-410.[doi:10.13798/j.issn.1009-153X.2024.07.005]
　WANG Xiao-wei,GAO Xue-jun,ZHANG Bo,et al.Pridiction of plasma differentially expressed miRNAs for postoperative recurrence of meningiomas[J].,2024,29(07):405-410.[doi:10.13798/j.issn.1009-153X.2024.07.005]
点击复制

血浆差异表达miRNA预测脑膜瘤术后复发()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年07期
页码:
405-410
栏目:
论著
出版日期:
2024-07-30

文章信息/Info

Title:
Pridiction of plasma differentially expressed miRNAs for postoperative recurrence of meningiomas
文章编号:
1009-153X（2024）07-0405-06
作者:
王晓伟; 高学军; 张波; 郑安锡; 罗霜
611130，成都市第五人民医院神经外科（王晓伟、高学军、张波、罗霜）；610081成都，成都大学附属医院神经外科（郑安锡）
Author(s):
WANG Xiao-wei1;  GAO Xue-jun1;  ZHANG Bo1;  ZHENG An-xi2;  LUO Shuang1
1. Department of Neurosurgery, Chengdu Fifth People's Hospital, Chengdu 611130, China; 2. Department of Neurosurgery, Chengdu University Affiliated Hospital, Chengdu 610081, China
关键词:
脑膜瘤; 术后复发; 血浆; 微小RNA
Keywords:
Meningioma;  Postoperative recurrence;  Plasma;  MicroRNA
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2024.07.005
文献标志码:
A
摘要:
目的 探讨血浆差异表达微小RNA（miRNA）在预测脑膜瘤术后复发中的作用。方法 2017年5~9月前瞻性收集5例脑膜瘤和5例健康体检者的血浆样本，采用TaqMan低密度阵列（TLDA）分析鉴定差异表达的miRNA。2017年11月至2023年11月前瞻性收集脑膜瘤97例，术前PCR检测血浆差异表达miRNA，末次随访复查MRI判断肿瘤复发情况。结果 TLDA分析共鉴定出9个差异表达miRNA（miR-21、miR-219-5p、miR-375、miR-190a、miR-451、miR-224、miR-107、miR-539、miR-197）。与未复发脑膜瘤病人比较，复发脑膜瘤病人血浆miR-21、miR-219-5p、miR-375、miR-190a表达量显著升高（P<0.05），血浆miR-451、miR-224、miR-107、miR-539、miR-197表达量显著降低（P<0.05）。末次随访，15例（15.46%）出现复发。多因素Cox回归分析显示，血浆miR-21、miR-219-5p、miR-190a高表达以及血浆miR-107、miR-539、miR-224低表达均与脑膜瘤术后复发密切相关（P<0.05）。Kaplan-Meier 曲线分析显示，血浆miR-21≥2.64、miR-219-5p≥2.72、miR-190a≥1.82以及血浆miR-107≤3.78、miR-539≤4.69、miR-224≤4.59病人肿瘤无复发生存时间明显缩短（P<0.05）。结论 脑膜瘤病人差异表达血浆miR-21、miR-219-5p、miR-375、miR-190a、miR-451、miR-107、miR-539、miR-224、miR-197，监测这些miRNA可辅助预测脑膜瘤术后复发风险。
Abstract:
Objective To explore the role of differentially expressed microRNAs (miRNAs) in plasma in predicting postoperative recurrence of meningiomas. Methods Plasma samples of 5 patients with meningiomas and 5 healthy subjects were prospectively collected from May to September 2017. TaqMan Low-Density Array (TLDA) analysis was used to identify differentially expressed miRNAs. Ninty-seven patients with meningiomas were prospectively collected from November 2017 to November 2023. Preoperative PCR was used to detect differentially expressed miRNAs in plasma, and tumor recurrence was determined by MRI at the last follow-up. Results A total of 9 differentially expressed miRNAs (miR-21, miR-219-5p, miR-375, miR-190a, miR-451, miR-224, miR-107, miR-539, miR-197) were identified by TLDA analysis. Compared with patients with non-recurrent meningiomas, the expression levels of miR-21, miR-219-5p, miR-375, and miR-190a in the plasma of patients with recurrent meningiomas were significantly increased (P<0.05), while the expression levels of miR-451, miR-224, miR-107, miR-539, and miR-197 in the plasma were significantly decreased (P<0.05). At the last follow-up, 15 patients (15.46%) had recurrence. Multivariate Cox regression analysis indicated that, high levels of miR-21, miR-219-5p, and miR-190a in plasma, and low levels of miR-107, miR-539, and miR-224 in plasma were closely related to postoperative recurrence of meningiomas (P<0.05). Kaplan-Meier curve analysis showed that patients with plasma miR-21 ≥2.64, miR-219-5p ≥2.72, miR-190a ≥1.82, and plasma miR-107 ≤3.78, miR-539 ≤4.69, and miR-224 ≤4.59 had significantly shorter recurrence-free survival time (P<0.05). Conclusion Patients with meningiomas have differentially expressed plasma miR-21,miR-219-5p, miR-375, miR-190a, miR-451, miR-107, miR-539, miR-224, miR-197, and miR-190a, and monitoring these miRNAs can assist in predicting the risk of postoperative recurrence of meningiomas.

参考文献/References:

[1]ROGERS CL, WON M, VOGELBAUM MA, et al. High-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539[J]. Int J Radiat Oncol Biol Phys, 2020, 106(4): 790-799.
[2]ZHOU L, TIAN RF, PAN K. Relationship between FASN and HER-2 expression and postoperative recurrence of meningiomas[J]. Chin J Clin Neurosurg, 2023, 28(4): 248-251. 周　龙，田仁富，潘　轲. 脑膜瘤FASN、HER-2的表达与术后复发的关系[J]. 中国临床神经外科杂志，2023，28（4）：248-251.
[3]NOWOSIELSKI M, GALLDIKS N, IGLSEDER S, et al. Diagnostic challenges in meningioma[J]. Neuro Oncol, 2017, 19(12): 1588-1598.
[4]GHAHRAMANI ALMANGHADIM H, GHORBIAN S, KHADEMIN S, et al. New insights into the importance of long non-coding RNAs in lung cancer: future clinical approaches[J]. DNA Cell Biol, 2021, 40(12): 1476-1494.
[5]BARAN O, KARAOGLU AC, KARA E, et al. Expression of miRNA-451 and miRNA-885 in meningiomas[J]. In Vivo, 2023, 37(6): 2473-2479.
[6]LUO ZX, CHEN YY, ZHANG YH, et al. Efficacy analysis of the large medial sphenoid ridge meningioma resection via extended pterional approach[J]. Chin J Neurosurg, 2023, 39(1): 14-18. 罗正祥，陈永严，张玉海，等. 经扩大翼点入路手术切除大型蝶骨嵴内侧型脑膜瘤的疗效分析[J]. 中华神经外科杂志，2023，39（1）：14-18.
[7]HILL M, TRAN N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4): dmm047662-dmm047670.
[8]STAFFORD MYC, WILLOUGHBY CE, WALSH CP, et al. Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis[J]. Biosci Rep, 2022, 42(1): BSR20211972-BSR20211980.
[9]ARGHIANI N, MATIN MM. miR-21: a key small molecule with great effects in combination cancer therapy[J]. Nucleic Acid Ther, 2021, 31(4): 271-283.
[10]KATAR S, BARAN O, EVRAN S, et al. Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma[J]. Clin Neurol Neurosurg, 2017, 156: 66-70.
[11]KILI? N, BOYACIOGLU ?, SALTOGLU GT, et al. Thioredoxin system and miR-21, miR-23a/b and let-7a as potential biomarkers for brain tumor progression: preliminary case data[J]. World Neurosurg, 2022, 167: e1299-e1309.
[12]RHIM J, BAEK W, SEO Y, et al. From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer[J]. Cells, 2022, 11(18): 2791-2809.
[13]HUANG WT, ZHANG H, JIN Z, et al. MiR-219-5p inhibits prostate cancer cell growth and metastasis by targeting HMGA2[J]. Eur Rev Med Pharmacol Sci, 2020, 24(9): 4710-4718.
[14]TANG S, JIANG H, CAO Z, et al. Down-regulation of miR-219-5p increase the risk of cancer-related mortality in patients with prostate cancer[J]. Postgrad Med J, 2022, 98(1162): 577-583.
[15]ZHI F, ZHOU G, WANG S, et al. A microRNA expression signature predicts meningioma recurrence[J]. Int J Cancer, 2013, 132(1): 128-136.
[16]ZHOU L, LI L, CHEN Y, et al. miR-190a-3p promotes proliferation and migration in glioma cells via YOD1[J]. Comput Math Methods Med, 2021, 2021(1): 3957738-3957750.
[17]ZHI F, SHAO N, LI B, et al. A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma[J]. Sci Rep, 2016, 6(1): 32067-32076.
[18]XING H, WANG S, LI Q, et al. Long noncoding RNA LINC00460 targets miR-539/MMP-9 to promote meningioma progression and metastasis[J]. Biomed Pharmacother, 2018, 105: 677-682.
[19]GHAFOURI-FARD S, ABAK A, HUSSEN BM, et al. The emerging role of non-coding RNAs in pituitary gland tumors and meningioma [J]. Cancers, 2021, 13(23): 5987-6006.
[20]FOIANI G, GUELFI G, MANDARA MT. MicroRNA dysregulation in canine meningioma: RT-qPCR analysis of formalin-fixed paraffin-embedded samples[J]. J Neuropathol Exp Neurol, 2021, 80 (8): 769-775.
[21]CHEN H, YAO J, SHAN Z, et al. To assess the role of microRNA-451 in the progression and metastasis of colorectal cancer[J]. Appl Biochem Biotechnol, 2024, 196(2): 1044-1057.

相似文献/References:

[1]李春坡　郑　军　李海元　边　涛　韩安国.侧脑室三角区小型脑膜瘤的显微外科治疗[J].中国临床神经外科杂志,2015,(11):694.[doi:10.13798/j.issn.1009-153X.2015.11.018]
[2]王林风　郑华山　操　廉.中央沟区矢状窦旁脑膜瘤的显微手术治疗（附25例报告）[J].中国临床神经外科杂志,2016,(07):431.[doi:10.13798/j.issn.1009-153X.2016.07.014]
[3]邓学云　刘　毅　范润金　刘丽华　夏祥国.E-cadherin与脑膜瘤分级及瘤周水肿的关系[J].中国临床神经外科杂志,2016,(04):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
　DENG Xue-yun,LIU Yi,FAN Run-jin,et al.Relationship of E-cadherin with the pathological grade of meningioma and peritumoral brain edema in patients with meningioma[J].,2016,(07):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
[4]马　磊　张海红　郭　康　孙树凯　张　亮　贾　栋.神经导航辅助下手术治疗侧脑室脑膜瘤1例[J].中国临床神经外科杂志,2016,(04):255.[doi:10.13798/j.issn.1009-153X.2016.04.023]
[5]王　一　崔焕喜　林令超　孙思辉　李绍山　周庆九　刘　波　柳　琛.侧脑室三角区脑膜瘤的显微手术治疗[J].中国临床神经外科杂志,2016,(03):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
　WANG Yi,CUI Huan-xi,LIN Ling-chao,et al.Microsurgery for meningiomas in the trigones of lateral ventricles (report of 47 cases)[J].,2016,(07):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
[6]王　鹏 综述　王　勇 审校.岩斜区脑膜瘤的手术入路[J].中国临床神经外科杂志,2016,(02):120.[doi:10.13798/j.issn.1009-153X.2016.02.024]
[7]漆松涛　刘　忆.关于WHO2007年版脑膜瘤病理分类一些问题的商榷[J].中国临床神经外科杂志,2016,(02):125.[doi:10.13798/j.issn.1009-153X.2016.02.026]
[8]李登辉　程　荆　李志强.镰旁脑膜瘤术后并发格林巴利综合征1例[J].中国临床神经外科杂志,2016,(02):72.[doi:10.13798/j.issn.1009-153X.2016.02.003]
[9]肖宗宇　陈晓娟　裴　杰　贺瑛福　许常林　马进海.超声吸引器在脑膜瘤手术切除中的应用[J].中国临床神经外科杂志,2015,(10):626.[doi:10.13798/j.issn.1009-153X.2015.10.016]
[10]杨　俊　吴雪松　莫鸿忠　潘荣南　赖　杰.双源CT三维血管成像技术在脑膜瘤术前评估中的应用[J].中国临床神经外科杂志,2015,(06):347.[doi:10.13798/j.issn.1009-153X.2015.06.009]
　YANG Jun,WU Xue-song,MO Hong-zhong,et al.Application of three-dimensional dual-source CT angiography to preoperative assessment of meningiomas[J].,2015,(07):347.[doi:10.13798/j.issn.1009-153X.2015.06.009]
[11]罗方接　张代龙　邓景阳等.人脑膜瘤组织β-catenin和Gal-3表达水平与术后复发的关系[J].中国临床神经外科杂志,2021,26(03):165.[doi:10.13798/j.issn.1009-153X.2021.03.007]
　LUO Fang-jie,ZHANG Dai-long,DENG Jing-yang,et al.Relationship between expression levels of β-catenin and Gal-3 in meningioma tissues and postoperative recurr-ence of patients with meningioma[J].,2021,26(07):165.[doi:10.13798/j.issn.1009-153X.2021.03.007]
[12]麦麦提依明·托合提,李金贤,乌拉别克·毛力提,等.脑膜瘤Nestin表达与术后复发的关系[J].中国临床神经外科杂志,2022,27(06):444.[doi:10.13798/j.issn.1009-153X.2022.06.004]
　MAITIYIMING Tuoheti,LI Jin-xian,ULABEK Maoliti,et al.Nestin expression in meningioma tissues and its clinical significance[J].,2022,27(07):444.[doi:10.13798/j.issn.1009-153X.2022.06.004]
[13]罗显华,张淳化,罗长稳,等.人脑膜瘤组织Slit2、Robo1的表达与术后复发的关系[J].中国临床神经外科杂志,2022,27(09):754.[doi:10.13798/j.issn.1009-153X.2022.09.011]
　LUO Xian-hua,ZHANG Chun-hua,LUO Chang-wen,et al.Relationship between expressions of Slit2 and Robo1 in human meningioma tissues and postoperative recurrence[J].,2022,27(07):754.[doi:10.13798/j.issn.1009-153X.2022.09.011]
[14]黄传平,刘忆,梁浩欣,等.脑膜瘤多次术后复发并恶变的靶向治疗分析：附1例报道并文献复习[J].中国临床神经外科杂志,2022,27(11):902.[doi:10.13798/j.issn.1009-153X.2022.11.007]
　HUANG Chuan-ping,LIU Yi,LIANG Hao-xin,et al.Analysis of targeted therapy for recurrent meningiomas associated with malignant transformation: report of one case and literature review[J].,2022,27(07):902.[doi:10.13798/j.issn.1009-153X.2022.11.007]
[15]周龙,田仁富,潘轲.脑膜瘤FASN、HER-2的表达与术后复发的关系[J].中国临床神经外科杂志,2023,28(04):248.[doi:10.13798/j.issn.1009-153X.2023.04.007]
　ZHOU Long,TIAN Ren-fu,PAN Ke.Relationship between FASN and HER-2 expression and postoperative recurrence of meningiomas[J].,2023,28(07):248.[doi:10.13798/j.issn.1009-153X.2023.04.007]

备注/Memo

备注/Memo:
（2024-02-29收稿，2024-05-20修回）
基金项目：成都市医学科研课题项目（2021095）
通信作者：罗　霜，Email：419743275@qq.com
更新日期/Last Update: 2024-07-30